Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease

Marie C. Hogan,* Tetyana V. Masyuk,† Linda J. Page,* Vickie J. Kubly,* Eric J. Bergstralh,‡ Xujian Li,‡ Bohyun Kim,§ Bernard F. King,§ James Glockner,§ David R. Holmes III,‖ Sandro Rossetti,* Peter C. Harris,* Nicholas F. LaRusso,† and Vicente E. Torres*

*Division of Nephrology and Hypertension, †Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Departments of ‡Biomedical Statistics and Informatics and §Radiology, and ‖Biomedical Imaging Research Core Facility, Mayo Clinic College of Medicine, Rochester, Minnesota

ABSTRACT
There are no proven, effective therapies for polycystic kidney disease (PKD) or polycystic liver disease (PLD). We enrolled 42 patients with severe PLD resulting from autosomal dominant PKD (ADPKD) or autosomal dominant PLD (ADPLD) in a randomized, double-blind, placebo-controlled trial of octreotide, a long-acting somatostatin analogue. We randomly assigned 42 patients in a 2:1 ratio to octreotide LAR depot (up to 40 mg every 28±5 days) or placebo for 1 year. The primary end point was percent change in liver volume from baseline to 1 year, measured by MRI. Secondary end points were changes in total kidney volume, GFR, quality of life, safety, vital signs, and clinical laboratory tests. Thirty-four patients had ADPKD, and eight had ADPLD. Liver volume decreased by 4.95%±6.77% in the octreotide group but remained practically unchanged (0.92%±8.33%) in the placebo group (P=0.048). Among patients with ADPKD, total kidney volume remained practically unchanged (+0.25%±7.53%) in the octreotide group but increased by 8.61%±10.07% in the placebo group (P=0.045). Changes in GFR were similar in both groups. Octreotide was well tolerated; treated individuals reported an improved perception of bodily pain and physical activity. In summary, octreotide slowed the progressive increase in liver volume and total kidney volume, improved health perception among patients with PLD, and had an acceptable side effect profile.


Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of renal cysts and a variety of extrarenal manifestations of which polycystic liver disease (PLD) is the most common.1 It is caused by mutations in one of two genes: PKD1 or PKD2. PKD1 mutations are responsible for approximately 85% of clinically detected cases. Autosomal dominant PLD (ADPLD) also exists as a genetically distinct disease with few or absent renal cysts. Like ADPKD, ADPLD is genetically heterogeneous, with the first two genes identified (PRKCSH and SEC63) accounting for approximately one-third to one-half of isolated ADPLD cases.2–5

Chronic symptoms are frequently associated with massively enlarged PLD, including abdominal distension and pain, dyspnea, gastroesophageal reflux, and early satiety, which may lead to malnutrition, mechanical lower back pain, inferior vena cava, hepatic and portal vein compression (leading to hypotension

Received December 23, 2009. Accepted February 18, 2010.
Published online ahead of print. Publication date available at www.jasn.org.
This trial has been registered at www.clinicaltrials.gov (identifier NCT00426153).
Correspondence: Dr. Marie C. Hogan, Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Phone: 507-266-9364; Fax: 507-266-9315; E-mail: hogan.marie@mayo.edu
Copyright © 2010 by the American Society of Nephrology
and inferior vena cava thrombosis, hepatic venous outflow obstruction, and portal hypertension), and biliary obstruction. Surgical approaches may be associated with definitive palliation but are also associated with a risk of morbidity and mortality.6

Liver cysts arise by excessive proliferation of cholangiocytes and dilation of biliary ductules and peribiliary glands. Alterations in intracellular calcium homeostasis and 3'5'-cAMP stimulate mitogen-activated protein kinase-mediated cell proliferation and cystic fibrosis transmembrane conductance regulator-driven chloride and fluid secretion.7 Cyst growth is enhanced by growth factors and cytokines secreted into the cyst fluid.8 Downstream activation of mTOR likely contributes to cystogenesis.9 Somatostatin may blunt cyst development by acting at multiple levels: inhibition of secretin release by the pancreas10; inhibition of secretin-induced cAMP generation and fluid secretion in cholangiocytes11–13; vasopressin-induced cAMP generation and water permeability in collecting ducts14–17 by its effects on Gi protein-coupled receptors; and suppression of the expression of IGF-1, vascular endothelial growth factor, and other cystogenic growth factors and of downstream signaling from their receptors.14–18

To determine whether octreotide could be effective in the treatment of PLD, we examined the effects of octreotide in the PCK rat, a recessive model of polycystic liver and kidney disease. We found that octreotide significantly reduced cAMP levels and hepatic cystogenesis in vitro and in vivo.19 In patients who underwent liver resections for massive PLD, we had observed that administration of octreotide reduced the rate of fluid secretion from unroofed cysts. In one patient with persistent ascites, intramuscular administration of octreotide LAR 40 mg monthly for 8 months was accompanied by a 17.8% reduction in liver volume from 2833 ml to 2330 ml (Figure 1). Two similar instances have been recently reported by van Keimpema et al.20 Finally, a pilot study showed that administration of octreotide LAR significantly inhibited kidney and cyst enlargement in patients with ADPKD.21 Encouraged by the results of the preclinical studies, anecdotal clinical experiences, and the pilot study in ADPKD, we initiated a pilot randomized, placebo-controlled, double-blind clinical trial of octreotide LAR in severe PLD.

RESULTS

A study flow diagram summarizing participant screening, enrollment, randomization, and disposition is shown in Figure 2.

Baseline Characteristics

Baseline patient characteristics were similar between the two groups (Table 1). Of the 42 patients who underwent randomization, 28 were assigned to receive octreotide and 14 to receive placebo. Five enrolled patients had a history of liver cyst aspiration/sclerosis, seven of liver fenestration (four octreotide, three placebo), and four of liver resection (one assigned octreotide and three to placebo). At least five had been offered a liver transplant. Four patients (three in the octreotide and one in the placebo group) had undergone renal transplantation before enrollment, and one patient (in the placebo group) had bilateral nephrectomies before transplantation. Three were receiving cyclosporine with azathioprine/mycophenolate mofetil, and one was receiving prednisone and mycophenolate mofetil. No patients were on sirolimus. For the analysis of kidney data, 13 patients were excluded because of a diagnosis of ADPLD (eight patients: four to octreotide, four to placebo), renal transplantation (four patients), and missing kidney data due to incomplete image coverage (one patient, assigned to placebo). Baseline liver volumes ranged from 2234 to 11,766 ml in the octreotide group (n = 28) and from 2239 to 13,148 ml in the placebo group (n = 14). Baseline total kidney

Figure 1. Administration of octreotide LAR to a patient with severe PLD resulted in decreased liver and kidney volumes. CT axial sections immediately before (A) and after 8 months of treatment with octreotide (B) are shown. Total liver volume decreased by 18% from baseline, and total kidney volume decreased by 12%.
volumes ranged from 320 ml to 3352 ml in the octreotide group ($n = 28$) and from 443 to 1211 ml in the placebo group ($n = 14$).

**Patient Genotypes**
Thirty-four patients had ADPKD; of these, 25 had a **PKD1** mutation and six a **PKD2** mutation; in three patients no mutation was detected. ADPKD and ADPLD genotypes and phenotypes were equally distributed between the octreotide and placebo groups (Table 1).

**Main Outcomes**

**Liver Volumes.**
Liver volumes in the octreotide group were $5907.7 \pm 2915.0$ ml at baseline and $11,766.1$ ml at 12 months, respectively (Figure 3A). Liver volumes in the placebo group were $5373.9 \pm 3565.4$ ml at baseline and $13,148.1$ ml at 12-month visits, respectively. Twenty-one of the 28 octreotide-treated patients experienced a reduction in liver volume during the 12 months of treatment; this was not affected by the underlying genotype (Figure 3B). On average, liver volume decreased by $4.95\% \pm 6.77\%$ in the octreotide group compared with a small increase ($0.92\% \pm 8.33\%$) in the

![Study flow diagram. Protocol violations were as follows: In the octreotide (Oct) arm, five injections of masked study drug and two study visits occurred outside of the protocol window. One 24-hour urine collection was obtained after the study visit. In the placebo arm, two injections of masked study drug and one study visit occurred outside of the protocol window.](Image)
Kidney Volumes.
Thirteen patients were excluded from the kidney analysis (see Baseline Characteristics for details). Total kidney volumes in the octreotide group were 1143 ± 827 ml and 1129 ± 796 ml at the baseline and 12-month visits, respectively (Figure 4A). Total kidney volumes in the placebo group were 803 ± 269 ml and 874 ± 306 ml at the baseline and 12-month visits, respectively (Figure 4A). Five of eight patients in the placebo group experienced an increase in total kidney volume during the 12 months of treatment (Figure 4B). In the placebo group, total kidney volumes increased by 8.61% ± 10.07% compared with 0.25% ± 7.53% in the octreotide group \((P = 0.045, \text{rank-sum test; Figure 4C})\). Changes in kidney volume in response to octreotide treatment were significantly correlated with baseline kidney volumes—patients with larger kidneys had larger reductions (Figure 4D).

Secondary Outcomes

Kidney Function.
GFR measured by iothalamate clearance in 30 ADPKD patients decreased from 68.1 to 64.6 ml/min per 1.73 m² (−5.1%) in the octreotide group \((n = 21)\) compared with a decrease from 70.1 to 65.7 ml/min per 1.73 m² (−7.2%) in the placebo group \((n = 9; P = 0.98; \text{Table 2})\). There was no significant difference in the rates of change in serum creatinine between the octreotide (+3.5%) and the placebo (+5.6%) groups \((P = 0.56; \text{Table 2})\).

Quality of Life.
Two subdomains in the health-related quality of life (HRQoL) questionnaire (SF-36; Table 3)—that is, physical role, which assesses physical activity (60 to 74, \(P = 0.04\)) and bodily pain (68 to 76, \(P < 0.02\)—significantly improved in the octreotide-treated group. No significant changes were seen in the placebo-treated group. No other HRQoL subdomains changed significantly over the course of the study.

Tolerability
Eighteen patients had symptoms after the test dose; 11 had mild diarrhea, five had abdominal cramps, six developed nausea, two complained of gas, and one each had vomiting, dizziness, and headache. One patient with moderate diarrhea after the test dose was initiated on a reduced dose (20 mg). The target dose was reached in 41 (97%) of 42 patients. Seven octreotide doses were withheld in three patients (Figure 5). The dose was reduced to 30 mg in seven and 20 mg in four patients receiving octreotide, mostly because of diarrhea/loose stools, especially in the first 2 weeks after an injection (Figure 5). The commonest reported side effect was injection site pain: 21 (75%) of 28 compared with 3 (21%)
of 14 on placebo. Injection site granulomas were reported in 5 of 28 patients receiving octreotide, with no occurrence in the placebo group.

Diarrhea grade 1 (an increase of less than four stools per day over baseline) was reported in 17 (61%) of 28, and abdominal cramping, bloating, and gas in 14 (50%) of 28 patients in the octreotide arm compared with 4 (28%) of 14 and 3 (21%) of 14, respectively, in the placebo arm. One patient on octreotide developed steatorrhea and weight loss. Despite withholding four doses and later recommencement of 20 mg while on pancreatic supplements, his symptoms persisted. Because he completed the 12 months in the study, his data were included in the analysis.

Asymptomatic nonobstructing cholelithiasis was identified in one patient, and another had gallbladder sludge. Both findings were present before assignment to octreotide and remained clinically stable on therapy.

One patient developed moderate alopecia after three full doses. Octreotide was held for 2 months for hair regrowth and then restarted 20 mg for 1 month and increased to 30 mg until completion with minimal hair loss.

One patient receiving octreotide developed symptomatic bradycardia requiring an emergency room visit after her sixth 40-mg dose. One dose was held, and then the participant was recommenced on 20 mg for 5 months and then increased to 30 mg. No patient receiving placebo required a dose reduction.

**Safety**

Over the 1-year study period, three patients receiving octreotide were hospitalized for causes deemed to be unrelated to the study intervention (bacteremia associated with nephrolithiasis and a urinary infection, abdominal pain and fever responding to antibiotic treatment, and incarcerated abdominal hernia). No serious adverse events occurred in the first year in the patients receiving placebo.

Plasma glucose levels increased 10% from baseline compared with a 2% increase in placebo ($p < 0.02$) after commencing octreotide treatment, but no patient developed diabetes (Table 2). No significant fluctuations in cyclosporin levels were observed in the three renal transplant recipients receiving both medications.

**DISCUSSION**

A large body of evidence has established that cAMP plays a central role in the progression of cystic disease in patients with ADPKD and/or ADPLD by stimulating mural epithelial cell proliferation and secretion of fluid into cysts. This has provided a strong rationale for therapies targeting cAMP and cAMP signaling. The ability to hormonally modulate cAMP signaling in a tissue/cell-specific manner provides a strategy that minimizes adverse effects on unaffected tissues or cells, which is obviously very important when considering treat-
ments for a chronic disease, such as ADPKD or ADPLD. For example, blocking the effect of vasopressin on the Gi protein-coupled receptor V2 in the kidney, thereby decreasing cAMP levels, inhibits renal cyst and kidney enlargement and improves renal function in four different genetic models of PKD, and clinical trials of vasopressin V2 receptor antagonists are in progress. V2 receptor antagonists have no effect on PLD because V2 receptors are not expressed in the liver.

Somatostatin analogs acting on Gi protein-coupled receptors provide an alternative path to inhibit cAMP signaling in cholangiocytes, as well as in tubular epithelial cells, thus potentially improving PLD in addition to PKD. We have recently shown that octreotide significantly reduces cAMP levels and rates of cyst expansion in freshly isolated bile ducts from PCK rats grown in 3D culture. Further, intraperitoneal injection of octreotide to PCK rats for 4 to 16 weeks lowered cAMP levels in serum and freshly isolated bile ducts and decreased liver and kidney weights and cystic and fibrosis scores. These effects were deemed to be mediated by Gi protein-coupled SST2 receptors in cholangiocytes, as well as in the distal nephron and collecting duct. Somatostatin is also known to blunt secretin-dependent urinary concentration along with vasopressin. Somatostatin also suppresses the expression of IGF-1, vascular endothelial growth factor, and other cystogenic growth factors and downstream signaling from their receptors. Therefore, somatostatin analogs may reduce cAMP accumulation and cyst growth by multiple mechanisms.

We initiated a clinical trial of octreotide in patients with severe PLD encouraged by the results of our preclinical studies, our anecdotal clinical experiences, and the pilot study conducted by Ruggenenti et al. The results of the clinical trial reported here show that administration of octreotide LAR for 1 year induced a moderate but significant reduction in liver volume, inhibited the growth of polycystic kidneys, and improved quality of life in patients with ADPKD and/or ADPLD, with low toxicity and few side effects. These results, in a group of genetically well-characterized patients with more severe PLD, treated for a more extended period of time, and with a positive outcome on quality of life, expand observations in two previous randomized, placebo-controlled trials. A crossover study of octreotide LAR (40 mg intramuscularly every 4 weeks) for 6 months in 12 ADPKD patients with advanced renal disease (mean total kidney volume 2435 ml, mean serum creatinine 1.9 mg/dl) showed that kidney volume increased by 2.2% ± 3.7% during active treatment compared with 5.9% ± 5.4% (P < 0.01) while on placebo. A parallel-arm, double-blind trial of lanreotide (120 mg subcutaneously every 4 weeks) for 6 months in 12 ADPKD patients with advanced renal disease showed that liver volume decreased 2.9%, from 4606 to 4471 ml, in the lanreotide group, whereas it increased 1.6%, from 4689 to 4895 ml, in the placebo group (P < 0.01). In the 32 patients with ADPKD, total kidney volume decreased 1.5%, from 1000 to 983 ml in the lanreotide group, whereas it increased 3.4%, from 1115 to 1165 ml in the placebo group (P < 0.02). A single subdomain score of the HRQol questionnaire (SF-36), current health perception, improved significantly in patients treated with lanreotide (P < 0.01). The dose of lan-

Table 2. Main clinical and laboratory parameters at start and end of treatment period

<table>
<thead>
<tr>
<th></th>
<th>Octreotide Baseline</th>
<th>Octreotide 12 mo</th>
<th>Delta %</th>
<th>Placebo Baseline</th>
<th>Placebo 12 mo</th>
<th>Delta %</th>
<th>P for Delta %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatinine, mg/dl</td>
<td>1.1 (0.43)</td>
<td>1.0 (0.47)</td>
<td>0.0 (0.12)</td>
<td>1.1 (0.52)</td>
<td>1.2 (0.62)</td>
<td>0.05 (0.12)</td>
<td>0.56</td>
</tr>
<tr>
<td>Iothalamate GFR, ml/min per 1.73 m²</td>
<td>68.1 (26.53)</td>
<td>64.6 (25.66)</td>
<td>−5.1 (15.46)</td>
<td>70.8 (28.08)</td>
<td>65.7 (26.40)</td>
<td>−7.2 (13.21)</td>
<td>0.98</td>
</tr>
<tr>
<td>Aspartate aminotransferase, U/L</td>
<td>32.5 (13.77)</td>
<td>29.9 (8.61)</td>
<td>−2.4 (23.66)</td>
<td>28.6 (7.93)</td>
<td>29.1 (6.11)</td>
<td>5.2 (17.93)</td>
<td>0.23</td>
</tr>
<tr>
<td>Albumin, g/dl</td>
<td>4.3 (0.18)</td>
<td>4.3 (0.20)</td>
<td>0.4 (4.47)</td>
<td>4.4 (0.19)</td>
<td>4.4 (0.19)</td>
<td>1.1 (4.54)</td>
<td>0.64</td>
</tr>
<tr>
<td>Bilirubin, μmol/L</td>
<td>0.6 (0.26)</td>
<td>0.6 (0.24)</td>
<td>17.5 (61.72)</td>
<td>1.0 (1.52)</td>
<td>0.7 (0.40)</td>
<td>−3.7 (34.09)</td>
<td>0.98</td>
</tr>
<tr>
<td>Alkaline phosphatase, U/L</td>
<td>92.5 (47.78)</td>
<td>99.0 (49.21)</td>
<td>9.8 (24.38)</td>
<td>107.5 (55.91)</td>
<td>101.4 (36.20)</td>
<td>−6.1 (14.91)</td>
<td>0.29</td>
</tr>
<tr>
<td>Prothrombin time, INR</td>
<td>9.6 (0.71)</td>
<td>10.4 (0.66)</td>
<td>7.5 (4.98)</td>
<td>10.9 (5.22)</td>
<td>10.5 (1.59)</td>
<td>2.8 (15.61)</td>
<td>0.83</td>
</tr>
<tr>
<td>Sodium, mEq/L</td>
<td>139.0 (3.05)</td>
<td>138.0 (3.30)</td>
<td>−0.7 (2.67)</td>
<td>139.2 (2.58)</td>
<td>139.2 (2.08)</td>
<td>0.0 (1.86)</td>
<td>0.12</td>
</tr>
<tr>
<td>Potassium, mEq/L</td>
<td>4.5 (0.46)</td>
<td>4.4 (0.35)</td>
<td>−1.5 (8.61)</td>
<td>4.3 (0.44)</td>
<td>4.4 (0.43)</td>
<td>3.2 (15.85)</td>
<td>0.48</td>
</tr>
<tr>
<td>Blood glucose, mg/dl</td>
<td>93.4 (11.22)</td>
<td>102.4 (11.54)</td>
<td>10.2 (11.25)</td>
<td>93.6 (7.81)</td>
<td>95.3 (8.01)</td>
<td>2.0 (7.10)</td>
<td>0.02</td>
</tr>
<tr>
<td>BUN, mg/dl</td>
<td>19.0 (7.23)</td>
<td>19.0 (7.37)</td>
<td>0.5 (19.72)</td>
<td>18.5 (7.66)</td>
<td>22.1 (10.50)</td>
<td>18.2 (21.40)</td>
<td>0.03</td>
</tr>
<tr>
<td>Hemoglobin, g/dl</td>
<td>12.8 (1.24)</td>
<td>12.6 (1.38)</td>
<td>−1.1 (5.31)</td>
<td>12.9 (0.97)</td>
<td>12.7 (1.14)</td>
<td>−1.4 (8.44)</td>
<td>0.74</td>
</tr>
<tr>
<td>Liver volume, ml</td>
<td>5907.7 (2915.0)</td>
<td>5557.1 (2659.4)</td>
<td>−3.7 (34.09)</td>
<td>5373.9 (3565.4)</td>
<td>5360.6 (3330.9)</td>
<td>0.9 (8.33)</td>
<td>0.04</td>
</tr>
<tr>
<td>Kidney volume, ml²b</td>
<td>1142.9 (826.9)</td>
<td>1128.5 (796.0)</td>
<td>0.25 (7.53)</td>
<td>803.0 (269.1)</td>
<td>873.5 (306.2)</td>
<td>8.61 (10.07)</td>
<td>0.045</td>
</tr>
</tbody>
</table>

Data shown as mean (SD). BUN, blood urea nitrogen.

Kidney volume/GFR: four transplant patients, eight ADPLD patients, and one patient with missing values were removed from this analysis.

P < 0.05 octreotide versus placebo group.
Table 3. Patient reported outcomes using mean health-related quality of life scores

<table>
<thead>
<tr>
<th>SF-36</th>
<th>Octreotide</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical functioning</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>time 0</td>
<td>74.8 (21.96)</td>
<td>80.4 (23.73)</td>
</tr>
<tr>
<td>12 mo</td>
<td>77.0 (21.32)</td>
<td>82.1 (18.58)</td>
</tr>
<tr>
<td>(P)</td>
<td>0.4013</td>
<td>0.5668</td>
</tr>
<tr>
<td><strong>Physical role</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>time 0</td>
<td>59.8 (42.13)</td>
<td>76.8 (39.79)</td>
</tr>
<tr>
<td>12 mo</td>
<td>74.1 (35.00)</td>
<td>75.0 (41.60)</td>
</tr>
<tr>
<td>(P)</td>
<td>0.0381*</td>
<td>0.8555</td>
</tr>
<tr>
<td><strong>Bodily pain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>time 0</td>
<td>67.8 (15.29)</td>
<td>65.5 (24.25)</td>
</tr>
<tr>
<td>12 mo</td>
<td>75.7 (19.02)</td>
<td>68.7 (25.51)</td>
</tr>
<tr>
<td>(P)</td>
<td>0.0158*</td>
<td>0.4653</td>
</tr>
<tr>
<td><strong>General health</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>time 0</td>
<td>55.9 (21.29)</td>
<td>58.0 (23.63)</td>
</tr>
<tr>
<td>12 mo</td>
<td>53.5 (17.32)</td>
<td>63.4 (23.96)</td>
</tr>
<tr>
<td>(P)</td>
<td>0.5265</td>
<td>0.1975</td>
</tr>
<tr>
<td><strong>Vitality</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>time 0</td>
<td>49.6 (21.81)</td>
<td>53.9 (25.96)</td>
</tr>
<tr>
<td>12 mo</td>
<td>54.4 (24.23)</td>
<td>54.6 (27.91)</td>
</tr>
<tr>
<td>(P)</td>
<td>0.2414</td>
<td>0.7801</td>
</tr>
<tr>
<td><strong>Social functioning</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>time 0</td>
<td>79.0 (19.56)</td>
<td>75.0 (27.30)</td>
</tr>
<tr>
<td>12 mo</td>
<td>82.9 (19.35)</td>
<td>81.3 (21.79)</td>
</tr>
<tr>
<td>(P)</td>
<td>0.2653</td>
<td>0.1309</td>
</tr>
<tr>
<td><strong>Role emotional</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>time 0</td>
<td>82.1 (32.05)</td>
<td>73.8 (37.39)</td>
</tr>
<tr>
<td>12 mo</td>
<td>91.4 (23.74)</td>
<td>81.0 (38.60)</td>
</tr>
<tr>
<td>(P)</td>
<td>0.2557</td>
<td>0.4874</td>
</tr>
<tr>
<td><strong>Mental health</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>time 0</td>
<td>76.0 (14.12)</td>
<td>75.4 (18.75)</td>
</tr>
<tr>
<td>12 mo</td>
<td>76.9 (16.54)</td>
<td>80.7 (18.76)</td>
</tr>
<tr>
<td>(P)</td>
<td>0.8734</td>
<td>0.2030</td>
</tr>
<tr>
<td><strong>Standardized physical component scale</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>time 0</td>
<td>42.6 (9.73)</td>
<td>46.0 (10.16)</td>
</tr>
<tr>
<td>12 mo</td>
<td>44.7 (10.00)</td>
<td>46.1 (9.51)</td>
</tr>
<tr>
<td>(P)</td>
<td>0.0563</td>
<td>0.9235</td>
</tr>
<tr>
<td><strong>Standardized mental component scale</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>time 0</td>
<td>50.8 (7.74)</td>
<td>48.4 (10.96)</td>
</tr>
<tr>
<td>12 mo</td>
<td>52.2 (8.03)</td>
<td>51.3 (11.15)</td>
</tr>
<tr>
<td>(P)</td>
<td>0.5049</td>
<td>0.0738</td>
</tr>
</tbody>
</table>

Data are mean (SD). Scored on a range of 0 to 100 (0 = worst imaginable, 100 = best imaginable). \(P\) (paired t test). *\(P\) < 0.05 within group.

Octreotide used in this study is equivalent to 60 mg of octreotide (compared with 40 mg used in our study), but lanreotide has a lower affinity for the SST2 receptor than octreotide.

The administration of octreotide or lanreotide has been generally well tolerated, with mostly mild, predictable, and dose-dependent gastrointestinal side effects. A single patient in our study had pre-existing gallstones, and another with gallbladder sludge remained stable on octreotide therapy. Patients undergoing long-term octreotide treatment should be monitored for cholelithiasis symptoms or signs because this is a known complication.31–36 One patient developed steatorrhea and weight loss, also a recognized side effect.37,38 A drawback of these treatments is the pain and granuloma formation associated with the injections. No significant fluctuations in cyclosporin levels were observed in the three renal transplant recipients taking octreotide with this medication.39

In summary, three independent randomized, placebo-controlled trials have had encouraging outcomes. Nevertheless, conclusions regarding safety and efficacy are limited by their short duration (6 to 12 months) and small number of subjects. Longer and larger clinical trials will be necessary to establish the long-term safety and efficacy of somatostatin analogs for ADPKD and/or ADPLD. Finally, combination therapies, including somatostatin analogs and other promising treatments, may in the future improve the efficacy and reduce the toxicity of emerging therapies for ADPKD and/or ADPLD.

**CONCISE METHODS**

**Study Design**

This was a single-center (Mayo Clinic, Rochester, MN), placebo-controlled, double-blind trial with a 2:1 randomization. It conformed to the principles of the Declaration of Helsinki and was approved by the Mayo Clinic Institutional Review Board. Patients were randomly assigned to receive octreotide or placebo and followed for 1 year. The primary end point (percent change in liver volume from baseline) as measured by magnetic resonance imaging (MRI) (or computed tomography [CT] in three patients, see below) at 12 months, and secondary end points were changes in total kidney volume, GFR, quality of life (QOL SF-36v2TM), and safety ascertained by reported adverse events, vital signs, and clinical laboratory tests. Novartis USA partially funded the study and supplied octreotide. The sponsor was not involved in the study design, in the enrollment of patients, or in the collection, analysis, data interpretation, or preparation of the manuscript. The manuscript was prepared by the authors and reviewed by the sponsor. The CONSORT guidelines were adhered to for all aspects of the conduct and manuscript writing of this clinical trial (www.consort-statement.org).

**Eligibility**

Men and women 18 years or older with a diagnosis of ADPKD or ADPLD, severe PLD defined as a liver volume >4000 ml or symptomatic disease due to mass effects from hepatic cysts, and who were not candidates or declining surgical intervention were eligible. Criteria for exclusion were inability to provide informed consent, women of childbearing potential unwilling to employ adequate contraception, serum creatinine concentration >3 mg/dl or dialysis dependency, symptomatic gallstones or biliary sludge, uncontrolled hypertension (SBP >160 mmHg; DBP >100 mmHg) or diabetes mellitus, cancer or major systemic diseases that could prevent completion of the planned follow-up or interfere with data collection or interpretation, and current or prior use of somatostatin analog within 6 months of enrollment or history of significant adverse reaction from a somatostatin analog.
Enrollment, Randomization, and Study Protocol
Enrollment took place from January 1, 2007, to May 19, 2008. Randomization (2:1) was performed to ensure that two-thirds of patients received Sandostatin LAR® (a long-acting depot form of octreotide that is administered intramuscularly once every 4 weeks) and one-third received placebo. Randomization assignment to octreotide or matching placebo treatment was independently managed by the research pharmacy. After verification of baseline eligibility data by the principal investigator and signature of written informed consent and consent for genotyping for PKD1 and PKD2 (and PKRSCH or SEC63), all women of childbearing age had a pregnancy test, and all patients were given a subcutaneous test dose of 100 µg of short-acting octreotide (Sandostatin®) and observed (vital signs) over a 4-hour period. The next day, after confirming tolerability of the test dose, they were given 40 mg of octreotide LAR in two 20-mg intramuscular injections (one in each buttock by nursing staff in the Center for Translational Science Activities [CTSA]) or placebo. Octreotide or placebo was continued at a dose of 40 mg by intramuscular injection every 28 ± 5 days. If needed because of side effects, the dose could be reduced to 30 or 20 mg. Patients returned for follow-up visits at 1, 4, 8, and 12 months for safety assessments, which included vital signs and physical examination and clinical laboratory parameters. MR or CT imaging of liver and kidneys was obtained at the baseline and 12-month visits.

Evaluation of Outcomes
Liver and kidney volumes were measured by MR or CT imaging. GFR was measured by clearance of iothalamate using a nonisotopic capillary electrophoresis-based method with monitoring of bladder emptying using ultrasound.40 Quality of life was assessed with the study form 36 SF-36 questionnaire administered at baseline and every 4 months thereafter. The SF-36 comprises nine minor domains (physical functioning, social functioning, physical role functioning, emotional role functioning, mental health, vitality, bodily pain, change in health perception, and general health perception), which are summarized into a physical and mental component. Safety laboratory studies were performed on all patients at baseline, week 4, and then at 4-month intervals thereafter. All adverse events occurring during the study were recorded according to National Cancer Institute Common Toxicity Criteria http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (version 3.0).41

MRI Scans and Volumetric Measurements
MRI was performed using a 1.5-T magnet on a single scanner using a torso phased-array surface coil. No intravenous gadolinium was used. MRI protocols included single-shot fast spin-echo (SSFSE), steady-state free precession (SSFP), and 3D fat-saturated spoiled gradient echo (3D SPGR) sequences. 3D SPGR sequences were the most suitable for volume analysis in the majority of patients. All images were acquired in coronal planes. The protocol was modified specifically to include patients with very large liver or kidneys, which often extended into the pelvis. Field of view ranged between 35 and 48 cm, and slice thickness was 4 mm with 0-mm gap. All sequences covered from dome of diaphragm to the lowermost portion of the kidneys. All sequences were obtained during breath hold. If the entire liver and kidney(s) could not be covered during one breath hold, more than one set of images, with neighboring image sets overlapped by one slice, were acquired. Depending on liver/kidney sizes and patient’s breath-holding capability, up to six sets of images were obtained for SSFSE and SSFP sequences, and up to two sets were obtained for 3D SPGR sequences.

In three patients, noncontrast CT was used for the analyses because MRI could not be performed: one claustrophobic individual, one oversized patient, and a third individual with a metallic ocular foreign body. Both initial and 1-year follow-up CTs were performed on a multi detector CT scanner using 5-mm thickness slices.

Image Analysis
Liver volumes (the primary end point) and total kidney volumes were measured at enrollment and at 1 year. The volumes of transplanted kidney and atrophic native kidneys were excluded from measurement in a total of four patients who underwent renal transplantation (three octreotide, one placebo). Eight patients with ADPLD (five on octreotide, three placebo) were excluded from the GFR and kidney volume analyses. One other ADPKD patient was excluded from the kidney volume analysis because of incomplete imaging coverage where kidney cysts extended deep into her pelvis.

Image analysis was performed by one of three image analysis specialists using a stereology approach implemented in the Mayo Clinic Analyze® software program http://www.mayo.edu/bir/Software/Analyze/Analyze.html.42,43 Stereology is a statistical sampling technique used to estimate shape parameters (such as volume, area, and surface area) from images.44 Three parameters (grid spacing in the x, y, and z direction) are required to conduct this analysis. To select appropriate parameters, four patients were selected for full segmentation. The entire liver and kidneys were segmented by hand. Different grid sizes with random offsets were systematically applied to the data, and the stereology-estimated volume was compared with the fully segmented volume. For liver volume calculation, a grid size of 20 × 20 × 2 voxels was selected, which yielded an average of 0.34% measurement error. For kidney volume calculation, a grid size of 10 × 10 × 1 voxels was selected, which yielded an average measurement error of 0.14%.

After completing each patient study, the marked images were verified by one of two radiologists who are specialized in abdominal MR imaging (B.F.K. and B.K.). The radiologists were blinded to patient treatment arm and timing of the scan for each subject (baseline or 1-year follow-up). Intrahepatic and intrarenal major vessels and porta hepatis vessels were included in all analyses. Kidney and liver volumes were obtained in one sitting for each individual patient. In some patients, the organ boundary of the liver and kidneys was difficult to delineate from that of the stomach, spleen, pancreas, and small and large bowel. In these patients, careful further correlation was made with the other sequences, including SSFSE and SSFP. Image analysis of CT images performed in three patients was similarly done.

Statistical Analysis
Sample size was determined on the basis of prior data in untreated patients suggesting a rate of kidney cyst growth of 5% ± 3% per year.45 A 2:1 randomization design allowed as many patients as possible to receive octreotide. The goal was to detect at least a three-
percentage point decrease in the mean liver cyst growth rate when using octreotide compared with placebo. With 13 placebo and 26 octreotide patients (allowing for an 8% dropout rate: one placebo and two octreotide patients without end point data), we estimated that the study would have 82% power (alpha = 0.05, two-sided) to detect a three-percentage point difference.46,47 Statistical analyses were performed using paired t test for within-group differences, also Wilcoxon rank-sum or Mann-Whitney tests were used to compare between-group differences. All reported P values were two sided, and P values <0.05 were considered statistically significant. For continuous parametric variables, values were reported as mean ± SD and range. All analyses were performed using SAS software, version 9.1 (SAS Institute, Cary, NC), and PRISM 4 was used for graphical data.

Molecular Characterization of the Study Cohort
Genomic DNA from each of the study cohort probands was extracted, and both \textit{PKD1} and \textit{PKD2} genes were fully sequenced for each phenotype defined ADPKD proband using previously described protocols.48,49 The ADPLD genes, \textit{SEC63} and \textit{PRKCSH},3,4 were fully sequenced in study cohort probands with an ADPLD phenotype. Mutation-negative patients were sequenced for all four genes. Genotype was assigned on the basis of the molecular findings, when a likely pathogenic mutation was found in one of the four genes sequenced, or on the basis of the clinical findings, when no likely pathogenic mutation was found.

ACKNOWLEDGMENTS

We are indebted to the patients who participated in the study, their families, and their physicians, and we thank the Angel Flight Organization for its assistance. Grant support was provided by Mayo Foundation for Medical Research and Novartis USA. This publication was made possible by grant 1 U11 RR024150 from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research in a research award to M.C.H. and resources in the Mayo CTSA Center.

DISCLOSURES

M.C.H. received partial funding support for this study from Novartis USA. N.F.L. and T.V.M. are named inventors on pending patent applications filed by Mayo Clinic claiming methods for using somatostatin analogs to treat polycystic liver disease.

REFERENCES

14. Forrest JN Jr., Reincln S, Goodman DB: Somatostatin: An endoge-
nous peptide in the toad urinary bladder inhibits vasopressin-stimu-
15. Friedlander G, Amiel C: Somatostatin and alpha 2-adrenergic agonists
selectively inhibit vasopressin-induced cyclic AMP accumulation in
on vasopressin-induced antidiuresis and renal cyclic AMP of rats.
17. Mountokalakis T, Levy M: Effect of somatostatin on renal water han-
19. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF: Octreotide
inhibits hepatic cystogenesis in a rodent model of polycystic liver
disease by reducing cholangiocyte adenosine 3',5'-cyclic monophos-
20. van Keimpema L, de Man RA, Drenth JP: Somatostatin analogues reduce
B, Remuzzi G, Epstein FH: Safety and efficacy of long-acting soma-
tostatin treatment in autosomal-dominant polycystic kidney disease.
Kidney Int 68: 206–216, 2005
22. Grantham JJ: Lilian Jean Kaplan International Prize for advancement
in the understanding of polycystic kidney disease. Underestimating
polycystic kidney disease: A systems biology approach. Kidney Int 64:
1157–1162, 2003
23. Gattone VH 2nd, Maser RL, Tian C, Rosenberg JM, Branden MG:
Developmental expression of urine concentration-associated genes
and their altered expression in murine infantile-type polycystic kidney
24. Gattone VH 2nd, Wang X, Harris PC, Torres VE: Inhibition of renal
cystic disease development and progression by a vasopressin V2
25. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd:
Effective treatment of an orthologous model of autosomal dominant
26. Wang X, Gattone V 2nd, Harris PC, Torres VE: Effectiveness of vasop-
ressin V2 receptor antagonists OPC-31260 and OPC-41061 on poly-
16: 846–851, 2005
27. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoff-
mann AL, Dekker HM, de Man RA, Drenth JP: Lanreotide reduces the
volume of polycystic liver: A randomized, double-blind, placebo-con-
of long term octreotide on gall stone formation and gall bladder
29. Davies PH, Steward WE, Lanaranjan L, Sheppard MC, Stewart PM:
Long-term therapy with long-acting octreotide (Sandostatin-LAR) for
30. Ho KY, Weissberger AJ, Marbach P, Lazarus L: Therapeutic efficacy of
the somatostatin analog SMS 201–995 (octreotide) in acromegaly.
J Clin Endocrinol Metab 88: 1827–1835, 2003
32. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen J, Kooij PP, de
Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion
JL, Krenning EP: Treatment of patients with gastro-entero-pancreatic
(GEP) tumours with the novel radiolabelled somatostatin analogue
417–422, 2003
33. Lami MC, Hadjadj S, Guillet G: Hair loss in three patients with acro-
34. Nakauchi Y, Kumor Y, Yamasaki H, Tahara K, Kurisaka M, Hashimoto
K: Scalp hair loss caused by octreotide in a patient with acromegaly:
35. Diliger JA, Rho EH, Que FG, Sprung J: Octreotide-induced bradycar-
dia and heart block during surgical resection of a carcinoid tumor.
Anesth Analg 98: 318–320, table of contents, 2004
36. Harrington AM, George KW, Moulds CC: Octreotide-induced brady-
biliary and pancreatic exocrine function, and induces steatorrhea in
39. Wagner MD, Prather JC, Barry JM: Selective, concurrent bilateral
nephrectomies at renal transplantation for autosomal dominant poly-
a nonisotopic capillary electrophoresis-based method for measuring glo-
41. National Cancer Institute: Common Terminology Criteria for Adverse
Events (CTCAE) and Common Toxicity Criteria (CTC) (see http://ctep.
42. Hanson DP, Robb RA, Aharon S, Augustine KE, Cameron BM, Camp JJ,
Kawoski RA, Larson AG, Stacy MC, Workman EL: New software toolkits
for comprehensive visualization and analysis of three-dimensional multi-
43. Roberts N, Puddephat MJ, McNulty V: The benefit of stereology for
In: Stereology for Biological Research with a Focus on Neuroscience.
Williston, VT, MBF Press, 2007
45. Grantham JJ, Torres VE, Chapman AB, Guay-woodford LM, Bae KT,
King BF Jr., Wetzel LH, Baumgarten DA, Kenney P, Harris PC, Klair
S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP,
CRISP Investigators: Volume progression in polycystic kidney disease.
46. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-wood-
ford LM, Baumgarten DA, King BF Jr., Wetzel LH, Kenney PJ, Brummer
ME, Bennett WM, Klair S, Meyers CM, Zhang X, Thompson PA, Miller JP; the Consortium for Radiologic Imaging Studies of Polycystic
Kidney Disease: Magnetic resonance imaging evaluation of hepatic
cysts in early autosomal-dominant polycystic kidney disease: The Con-
sortium for Radiologic Imaging Studies of Polycystic Kidney Disease
47. Everson GT: Hepatic cysts in autosomal dominant polycystic kidney
48. Rossett S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford
QJ, Thompson PA, Miller JP, Harris PC: Comprehensive molecular
diagnostics in autosomal dominant polycystic kidney disease. J Am
49. Rossett S, Kubly JV, Consugar MB, Hopp K, Roy S, Horsley SW,
Chauveau D, Rees L, Barratt TM, van’t Hoff WG, Niaudet WP, Torres
VE, Harris PC: Incompletely penetrant PKD1 alleles suggest a role for
75: 848–855, 2009

HORMONE MIMIC REDUCES LIVER DAMAGE CAUSED BY COMMON GENETIC KIDNEY DISEASE

Octreotide Provides Benefits for Both the Liver and Kidney in Patients with ADPKD

Washington, DC (April 26, 2010) — A hormone mimic called Octreotide may be effective for treating polycystic liver disease (PLD) caused by ADPKD, according to a study appearing in an upcoming issue of the *Journal of the American Society Nephrology* (JASN). The study is the first clinical trial performed in the United States to test the effects of this agent in PLD.

In addition to causing kidney failure, ADPKD also often leads to PLD, a condition characterized by multiple variably-sized cysts in the liver. Octreotide mimics the somatostatin hormone that regulates the secretion of several other hormones in the body. Somatostatin exerts its effects by blocking both the formation of the chemical cyclic AMP and the secretion of fluids by cells, two factors thought to play a role in the development of kidney and liver cystic diseases.

Marie Hogan, MD, PhD (Mayo Clinic College of Medicine) and her colleagues designed a clinical trial to examine whether Octreotide could shrink the cyst-filled livers of patients with PLD. The randomized, double-blind, placebo-controlled trial enrolled 42 patients with severe PLD caused by ADPKD (34 patients) or autosomal dominant PLD (8 patients). (Autosomal dominant PLD is a genetic form of PLD not caused by ADPKD.) Patients received Octreotide or placebo, and treatments were administered as monthly injections.

After one year, liver volume decreased by an average of approximately 5% in patients taking Octreotide but slightly increased (by approximately 1%) in patients taking placebo. Octreotide also had an effect on the diseased kidneys of patients with ADPKD. Among these patients, total kidney volume remained practically unchanged in the Octreotide group but increased by more than 8% on average in the placebo group. Kidney function was similar in both groups of patients. Octreotide was well tolerated, and treated individuals reported an improved perception of bodily pain and physical activity.

“In summary, Octreotide slowed the progressive increase in liver volume and total kidney volume, improved health perception among patients with PLD, and had an acceptable side effect profile,” said Dr. Hogan.
Study co-authors include Tetyana Masyuk, PhD, Linda Page, Vickie Kubly, Eric Bergstrahl, Xujian Li, Bohyun Kim, MD, Bernard King, MD, James Glockner, MD, PhD, David Holmes III, PhD, Sandro Rossetti, MD, PhD, Peter Harris, PhD, Nicholas LaRusso, MD, and Vicente Torres, MD, PhD (Mayo Clinic College of Medicine).

In reviewing the results of Dr. Hogan’s study in an accompanying editorial, Robert Schrier, MD (University of Colorado Denver) noted that they support the findings of earlier animal and human studies and give hope that increases in polycystic liver and kidney volume can be attenuated in patients with ADPKD. He added that additional, larger studies are needed to verify the results and to demonstrate whether Octreotide can provide meaningful health benefits to patients.

Disclosures: Funding support for the study was provided by Mayo Foundation for Medical Education and Research and Novartis USA. Dr. Hogan received partial funding support for this study from Novartis USA. Dr. LaRusso and Dr. Masyuk are named inventors on pending patent applications filed by Mayo Clinic claiming methods for using somatostatin analogs to treat polycystic liver disease. Dr. Schrier, the author of the editorial, is a consultant for Otsuka Pharmaceuticals.


The content of these articles does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966, the American Society of Nephrology (ASN) is the world’s largest professional society devoted to the study of kidney disease. Comprised of 11,000 physicians and scientists, ASN continues to promote expert patient care, to advance medical research, and to educate the renal community. ASN also informs policymakers about issues of importance to kidney doctors and their patients. ASN funds research, and through its world-renowned meetings and first-class publications, disseminates information and educational tools that empower physicians.

# # #